Namrah Siddiq
Hematology & Oncology · New Haven, CTNPI 1144682501
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,864 of the $4,387 with a category attached, or 88.1%. It is spread thinly across 33 manufacturers, the largest accounting for just 14.8% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,912, 5.6 times the $339 reported in 2021.
Across 175 payments — averaging $25.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$649
- Johnson & Johnson$379
- Daiichi Sankyo Inc.$373
- Lilly USA, LLC$229
- Amgen$216
- E.r. Squibb & Sons, L.L.C.$190
- plus $2K from 27 others
What the payments were for
- Food & beverage$3,86488%
- Education$52312%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 27 | $649 |
| Johnson & Johnson | 15 | $379 |
| Daiichi Sankyo Inc. | 14 | $373 |
| Lilly USA, LLC | 10 | $229 |
| Amgen | 3 | $216 |
| E.r. Squibb & Sons, L.L.C. | 10 | $190 |
| Merck | 8 | $190 |
| Gilead | 9 | $176 |
| Sanofi | 7 | $175 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $175 |
| Novartis | 8 | $173 |
| Eisai Inc. | 7 | $162 |
| Bristol Myers Squibb | 6 | $155 |
| Sobi, Inc | 6 | $146 |
| Regeneron Healthcare Solutions, Inc. | 5 | $114 |
| Davol Inc. | 3 | $104 |
| Pharmaessentia USA Corporation | 3 | $101 |
| Incyte Corporation | 2 | $95 |
| Geron Corporation | 3 | $69 |
| GSK | 3 | $68 |
| Pfizer | 3 | $65 |
| Seagen Inc. | 1 | $61 |
| Astellas Pharma US Inc | 2 | $56 |
| Pharmacosmos Therapeutics Inc. | 2 | $50 |
| Array Biopharma Inc | 2 | $46 |
| Immunocore Limited | 1 | $28 |
| Adaptive Biotechnologies Corporation | 1 | $25 |
| ADC Therapeutics America, Inc. | 1 | $25 |
| Caris MPI, Inc. | 1 | $20 |
| Stemline Therapeutics Inc. | 1 | $19 |
| Tempus AI, Inc | 1 | $19 |
| EMD Serono, Inc. | 1 | $18 |
| Agios Pharmaceuticals, Inc. | 1 | $17 |
How this compares
$4,387 in reported general payments places this provider in the 60th percentile of 163 hematology & oncology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 25 | $17,606 |
| XareltoRivaroxaban | 16 | $9,311 |
| Anastrozole | 36 | $601 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 14 | $326 |
| Dexamethasone | 24 | $268 |
| Ondansetron OdtOndansetron | 16 | $172 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $65 | $17,60625 claims |
| Johnson & JohnsonXarelto | $379 | $9,31116 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 163 hematology & oncology providers in Connecticut.
Other hematology & oncology in New Haven
- Amer ZeidanNew Haven$807K
- Walid ShaibNew Haven$217K
- Scott HuntingtonNew Haven$163K
- Nataliya UbohaNew Haven$124K
- Michael CecchiniNew Haven$103K
- Iris IsufiNew Haven$73K
- Maximilian StahlNew Haven$34K
- Shalin KothariNew Haven$24K
- John RobertsNew Haven$17K
- Biree AndemariamFarmington$646K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.